Clinical Trial Update: A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FDL169 in cystic fibrosis subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• FDL169

Snippet

Sponsor: Flatley Discovery Lab LLC | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED